Lysyl oxidase‐like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal‐like breast carcinomas-Reference-Cited by-同舟云学术

Lysyl oxidase‐like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal‐like breast carcinomas

Published:2011-07-06 Issue:9 Volume:3 Page:528-544
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Moreno‐Bueno Gema¹²,Salvador Fernando¹,Martín Alberto¹,Floristán Alfredo¹,Cuevas Eva P.¹,Santos Vanesa¹,Montes Amalia¹,Morales Saleta¹,Castilla Maria Angeles³,Rojo‐Sebastián Alejandro²,Martínez Alejandra⁴,Hardisson David⁴,Csiszar Katalin⁵,Portillo Francisco¹,Peinado Héctor¹⁶,Palacios José³,Cano Amparo¹

Affiliation:

1. Departamento de Bioquímica, UAM, Instituto de Investigaciones Biomédicas “Alberto Sols”, CSIC‐UAM, IdiPAZ, Instituto de Investigación Sanitaria La Paz, Madrid, Spain

2. MD Anderson Cancer Center Madrid, Spain

3. Unidad de Gestión Clínica de Anatomía Patológica and Grupo de Patología Molecular del Cáncer, Hospital Virgen del Rocío‐IBIS, Instituto Biosanitario de Sevilla, Sevilla, Spain

4. Departamento de Anatomía Patológica. Hospital La Paz‐IdiPAZ, Instituto de Investigación Sanitaria La Paz, Madrid, Spain

5. John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA

6. Departments of Pediatrics, Weill Medical College of Cornell University, 515E 71^st Street, New York 10021, USA

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/emmm.201100156

Reference62 articles.

1. The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity

2. Lysyl oxidase‐related protein‐1 promotes tumor fibrosis and tumor progression in vivo;Akiri G;Cancer Res,2003